The latest SARS-CoV-2 variant of concern Omicron, with its immune escape from therapeutic anti-Spike monoclonal antibodies and WA-1 vaccine-elicited sera, demonstrates …
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options has been studied and deployed. Healthcare providers have multiple treatment approaches …
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …
The epidemic of corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus 2 and its variants of concern (VOCs) has been ongoing for over 3 …
TO THE EDITOR—We read with interest the manuscript by Ando and colleagues in which the authors showed a high efficacy of amoxicillin-based regimens for syphilis in people with …
D Focosi, S Meschi, S Coen, MC Iorio… - Vox …, 2023 - Wiley Online Library
Background and Objectives COVID‐19 convalescent plasma (CCP) has retained potency and clinical efficacy against SARS‐CoV‐2 and is currently of utmost value for seronegative …
Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma sources Page 1 1 Analysis of anti-Omicron neutralizing antibody titers in different convalescent plasma …
H Schrezenmeier, S Hoffmann, H Hofmann… - …, 2023 - thieme-connect.com
COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently …
Influenzavirus is among the most relevant candidates for a next pandemic. We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly …